stockrow
Friday 6 November 2026
Export NPCE’s income statement to Excel — free account
NeuroPace, Inc.
NPCE Healthcare Medical Devices
NeuroPace, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $100.0 million, up 25.1% from fiscal 2024.
- Revenue
- −2.95%
- EPS
- +30.8%
- Free cash flow
- −78.7%
- Total debt
- +0.68%
Quarter to June 2026, against a year earlier
12.47
0.22
−1.73%
Follow NPCE
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 4 | 4 | 3 | 5 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
(2.52) | (4.67) | (4.09) | (5.37) | (1.91) | — | — | — |
P/S ratio |
5.05 | 4.08 | 3.86 | 0.78 | 3.71 | 0.16 | 0.16 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
(13.13) | (15.14) | (12.04) | (10.41) | (4.19) | (19.65) | (81.19) | — |
Beneish M-Score |
(2.88) | (2.96) | (2.58) | 47.37 | (3.15) | 2.78 | — | — |
P/Operating CF |
998.49 | (67.94) | (75.68) | (4.52) | (20.41) | (1.13) | (1.13) | — |
P/B ratio |
26.55 | 40.67 | 12.24 | 1.02 | 2.28 | 0.00 | 0.00 | — |
Price to Tangible BV |
26.55 | 40.67 | 12.24 | 1.02 | 2.28 | 0.00 | 0.00 | — |
EV/Sales |
5.07 | 4.21 | 3.77 | 0.32 | 2.33 | 0.69 | 0.69 | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
(46.03) | (18.74) | (12.53) | (0.39) | (4.28) | (1.40) | (1.40) | — |
EV/FCF |
(44.69) | (18.42) | (12.42) | (0.39) | (4.22) | (1.39) | (1.39) | — |
Quick Ratio |
4.25 | 4.33 | 4.85 | 7.73 | 13.19 | 4.84 | 0.15 | — |
Current Ratio |
5.28 | 5.37 | 5.71 | 8.90 | 14.28 | 5.69 | 0.27 | — |
Net Debt/EBITDA |
0.15 | (0.34) | 0.36 | 0.61 | 2.84 | (1.60) | (2.04) | — |
Debt/Assets |
55.78% | 62.89% | 52.91% | 46.37% | 37.32% | 94.48% | 209.35% | 0.00% |
Debt/Equity |
3.09 | 7.43 | 2.76 | 1.52 | 0.68 | (0.36) | (0.34) | — |
Asset Turnover |
1.00 | 0.79 | 0.59 | 0.37 | 0.48 | 1.07 | 3.51 | — |
Operating CF/Net income |
0.51 | 0.66 | 0.60 | 0.78 | 0.68 | 0.89 | 0.84 | — |
Capex/Depreciation |
(0.15) | (0.15) | (0.38) | (1.15) | (0.68) | (0.02) | (0.16) | — |
Interest Coverage |
(2.19) | (2.46) | (3.19) | (5.42) | (3.20) | (1.14) | (2.32) | — |
| (158.74%) | (189.35%) | (118.91%) | (86.96%) | 97.08% | 17.52% | 21.63% | — | |
| (21.44%) | (26.83%) | (29.72%) | (38.02%) | (38.08%) | (63.02%) | (284.17%) | — | |
ROIC |
(60.58%) | (91.62%) | (152.27%) | (247.99%) | (191.03%) | 0.00% | 0.00% | — |
Return on Tangible Assets |
(27.74%) | (40.37%) | (42.53%) | (53.62%) | (29.07%) | (53.38%) | 55.43% | — |
Average Days of Receivables |
53.59 | 58.70 | 68.70 | 59.99 | 57.28 | 74.49 | 59.40 | — |
Research and Development Expense of Revenue |
27.89% | 29.60% | 31.76% | 48.21% | 40.30% | 38.15% | 49.48% | — |
Selling, General and Administrative Expense of Revenue |
65.68% | 71.46% | 83.33% | 112.79% | 86.23% | 67.16% | 81.69% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
11.09% | 12.87% | 14.61% | 18.34% | 9.49% | 3.35% | 3.90% | — |
Graham Net Nets |
0.01 | (0.02) | 0.02 | 0.52 | 0.43 | (23.78) | (23.78) | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1,386.21 | 0.00 | — |
Earnings Yield |
(4.27%) | (8.49%) | (13.09%) | (133.33%) | (337.20%) | (472.13%) | (472.13%) | — |
Free Cash Flow Yield |
(2.24%) | (5.60%) | (7.86%) | (105.80%) | (14.91%) | (313.93%) | (313.93%) | — |
Revenue per Share |
3.06 | 2.74 | 2.53 | 1.85 | 2.72 | 200.67 | 183.12 | — |
Operating CF per Share |
(0.34) | (0.62) | (0.76) | (1.50) | (1.48) | (105.41) | (123.95) | — |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.02) | (0.02) | (0.30) | (2.30) | — |
Free Cash Flow per Share |
(0.35) | (0.63) | (0.77) | (1.52) | (1.50) | (105.71) | (126.25) | — |
Cash per Share |
1.87 | 1.81 | 2.57 | 3.15 | 6.96 | 185.75 | 25.22 | — |
Shareholders Equity per Share |
0.58 | 0.28 | 0.80 | 1.41 | 4.43 | (721.13) | (640.66) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
0.58 | 0.28 | 0.80 | 1.41 | 4.43 | (721.13) | (640.66) | — |
Free Cash Flow |
(11.34) | (18.25) | (19.87) | (37.47) | (24.96) | (21.67) | (25.49) | — |
Working Capital |
76.26 | 66.18 | 76.49 | 86.74 | 123.52 | 44.97 | (54.89) | — |
Capital Expenditures |
(0.33) | (0.31) | (0.17) | (0.60) | (0.38) | (0.06) | (0.46) | — |
Net Current Asset Value |
7.54 | (5.29) | 5.72 | 18.39 | 72.76 | (149.22) | (130.18) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.01 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
1.94 | 1.90 | 0.45 | 0.49 | 0.93 | 7.39 | 3.53 | — |
Cash ROIC |
(8.16%) | (15.18%) | (13.80%) | (22.70%) | (10.45%) | 38.09% | 31.82% | — |
Accounts Receivable Turnover |
7.26 | 6.35 | 6.61 | 6.25 | 5.84 | 5.71 | 5.13 | — |
Accounts Payable Turnover |
8.81 | 7.88 | 7.72 | 7.39 | 10.10 | 11.73 | 11.35 | — |
Inventory Turnover |
1.50 | 1.69 | 1.65 | 1.49 | 1.60 | 1.47 | 1.42 | — |
Average Days of Payables |
35.54 | 51.78 | 49.20 | 60.16 | 42.81 | 31.88 | 31.37 | — |
Days of Inventory on Hand |
270.89 | 234.57 | 236.61 | 272.12 | 243.02 | 232.08 | 274.41 | — |
Average Receivables |
13.77 | 12.58 | 9.90 | 7.29 | 7.74 | 7.21 | 7.21 | — |
Average Payables |
2.59 | 2.64 | 2.24 | 1.76 | 1.16 | 0.93 | 0.93 | — |
Average Inventory |
15.14 | 12.30 | 10.46 | 8.77 | 7.37 | 7.40 | 7.40 | — |
Average Assets |
100.11 | 101.15 | 110.88 | 123.83 | 94.76 | 38.52 | 10.55 | — |
Average Common Equity |
13.52 | 14.33 | 27.72 | 54.14 | (37.16) | (138.59) | (138.59) | — |
Columns are period end dates · fundamentals updated 26 Oct 2026